Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2023

Chen Jiayan, Xu Chunwei, Wang Qian, Lv Jiawen, Lu Wanjun, Zhang Yixue, Yao Yanwen, Gu Xiaoling, Wu Guannan, Hao Yue, Pan Weiwei, Wang Wenxian, Zhang Shirong, Lv Tangfeng, Song Yong, Wang Dong

Abstract excerpt

BACKGROUND: Although the treatment of ERBB2-altered non-small cell lung cancer (NSCLC) has been studied for many years, there are no comprehensive studies to evaluate the benefits of various therapies as first-line treatment. Through the development of immunotherapy, more and more different combination treatments were applicated in clinical practice, therefore, we conducted a multicenter retrospective study to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37517117
DOI: 10.1016/j.lungcan.2023.107315

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study.PMID 37517117Read ↗

[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor].Semantic proximity Read ↗

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.Semantic proximity Read ↗

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudySemantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

Clinical and molecular characteristics, transcriptome, and drug efficacy of ERBB2 tyrosine kinase and non-tyrosine kinase mutations in non-small cell lung cancerSemantic proximity Read ↗

[Research Progress of Targeted Therapy for HER2 Gene in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted TherapiesSemantic proximity Read ↗

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.